ClinicalTrials.gg
RecruitingNCT07674355LIVERSLEEPUpdated Nov 4, 2026

Study of Sleep Quality and Its Specific Determinants During the Care Pathway of a Liver Transplant Patient

An observational study in Liver Transplantation, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Sleep Initiation and Maintenance Disorders with a site in France — 19 open to participants now, 19 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · France.

Planned enrollment
6th of 16
108 · median 83
Started
2026
with 4 others
Observational
16 of 76
5 open now
Primary completion
2029-04
later than 18 of 18 live
Registered
74th of 76
by date
Lead sponsor
2 of 76
Hospices Civils de Lyon

Among the 76 studies in Sleep Initiation and Maintenance Disorders with a site in France, this one is the 6th largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2026, is one of 16 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 74th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

19 of the 76 studies in Sleep Initiation and Maintenance Disorders with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Sleep Initiation and Maintenance Disorders with a site in France, or all of them as a file.
02

Study summary

In the LIVERSLEEP study, investigators provide an overview of sleep disorders among patients in a liver transplantation (LT) pathway and a description of the criteria that can influence their sleep.

This is a prospective longitudinal monocentric pilot study, generating hypotheses whose main objective is to describe the evolution of sleep quality in LT patients between pre-LT evaluation (PLTE) and 6 months post-LT. The secondary objective(s) are, before LT, 2 months and 6 months after, (1) to describe the level of anxiety in our patients, (2) to estimate the proportion of patients with impaired sleep quality, and (3) to describe the characteristics of our patients' sleep.

This study will cover all adult patients on the LT waiting list at the Croix Rousse Hospital transplant center for the duration of the study. The duration of the inclusion period is 18 months. For each patient, the participation period will be 1 year on average (pre-LT measurement with an average waiting time of 6 months for LT, then measurements at TH+2 months and at TH+ 6 months). The total duration of the study will be 30 months, with a theoretical start of inclusions in the third quarter of 2026.

Patients likely to participate in the study will be identified by the transplant nurse coordinatoir (TNC) within the digestive surgery and LT department of the Croix-Rousse hospital in Lyon. These are all the patients seen in hepatology consultation for the announcement of a LT project. Verification of the selection or contraindication criteria will be carried out by the principal investigator.

During the consultation with the hepatologist and the TNC to announce the indication for LT, the study will be presented by the physician and then detailed by the TNC (objectives, steps, submission of upcoming questionnaires). After collecting the patient's non-opposition, clinical data will be collected (weight, height, BMI, sex, age, indication, MELD score, and presence or absence of hepatic encephalopathy). Given the emotional burden of this consultation, no questionnaire will be submitted to the patient at this stage.

During the PLTE, then 2 months and 6 months after LT, 5 questionnaires will need to be completed by the patient (evaluation of sleep quality, anxiety, chronotype, physical activity, and pain). The TNC also collects the presence of psychotropic treatments that can influence sleep.

A sleep schedule will be sent to the patient with their appointment for the PLTE and to be completed before hospitalization. This diary will be retrieved during the PLTE by the TNC. The presence or absence of psychotropic treatment will also be recorded.

Two and six months after the LT, during follow-up visits in ambulatory care, conventional hospitals, or consultations, the patient responds again to these five questionnaires on a tablet, and the TNC also collects the presence of psychotropic treatment.

Finally, at a distance from the LT (2 months later), the TNC collects the duration of the patient's transplant wait (from the date of activation on the waiting list to the LT date), the number of examinations performed during the PLTE, and post-LT complications (return to the operating room, stent-like endovascular treatment, drain adhered to the skin), the duration of the PLTE (date of the first PLTE examination on the date of activation on the waiting list) and the immediate post-LT hospitalization period (in days).

A comparative analysis will be conducted between patients whose sleep quality is altered and those for whom it is maintained, with some factors of interest related to the patient's clinic and care pathway.

The results will serve as a basis for the implementation of a relevant intervention aimed at treating and reducing sleep disorders in our patients.

03

Conditions studied

  • Liver Transplantation

Keywords

  • Liver transplantation
  • Quality of sleep
  • Transplant nurse coordinator (TNC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients registered on the liver transplantation waiting list at the Croix Rousse Hospital transplant center (France) for the duration of the study, except patients with organ failures whose indication for liver transplantation is carried during hospitalization in critical care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of legal age (age ≥ 18 years)
  • Patients with a liver transplantation indication during the study period
  • Patients who were informed and did not object to their participation in the study
  • Patients affiliated with a social security scheme or beneficiaries of a similar scheme

Exclusion criteria

Exclusion Criteria:

  • Patients with organ failures whose liver transplantation indication is carried during hospitalization in critical care (very short time between the indication and liver transplantation, causes of medical failure mainly related to the patient's death)
  • Patients with an indication for multi-organ transplantation
  • Narcolepsy
  • Persons deprived of liberty by a judicial or administrative decision
  • People receiving psychiatric care
  • Persons admitted to a health or social welfare institution for purposes other than research
  • Adults subject to a legal protection measure (guardianship, curatorship)
  • Inability to understand the information regarding the protocol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Score of Pittsburgh Sleep Quality Index (PSQI) scale

    The evolution of sleep quality will be described using the average score on the Pittsburgh Sleep Quality Index (PSQI) scale. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties

    Time frame: During the Pre-LiverTransplantation Evaluation, then at 2 and 6 months after LiverTransplantation.

07

Study locations

1 of 1 sites recruiting
  • Service de chirurgie digestive et de transplantation hépatique, Hôpital de la Croix-Rousse
    Lyon, 69004, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.

Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 30 months is above that.

Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Sep 2026 → Oct 2026, primary completion Mar 2029 → Apr 2029 and completion Mar 2029 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Oct 7, 2026was Sep 2026
Primary completionEst.
Apr 2029was Mar 2029
CompletionEst.
Apr 2029was Mar 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Service de chirurgie digestive et de transplantation hépatique, Hôpital de la Croix-Rousse is now Recruiting
Nov 4, 2026
Start date
Sep 2026→Oct 7, 2026 (actual)
Nov 4, 2026
Primary completion
Mar 2029→Apr 2029
Nov 4, 2026
Study completion
Mar 2029→Apr 2029
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Service de chirurgie digestive et de transplantation hépatique, Hôpital de la Croix-Rousse is now Recruiting
    Start date Sep 2026→Oct 7, 2026 (now actual)
    Primary completion Mar 2029→Apr 2029
    Study completion Mar 2029→Apr 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07674355
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Oct 7, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Julie GONZALEZ, Nurse
Contact
julie.gonzalez@chu-lyon.fr
4 72 07 19 93 ext. +33
Bénédicte POUMAROUX, Project manager
Contact
benedicte.poumaroux@chu-lyon.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion